

Background

- HER2-low status has been proposed as a potential treatment target for breast cancers previously considered to be HER2-negative
- HER2-low status predicts significant clinical benefit from novel therapeutic compounds in recent clinical trials

Conclusions

1. Patients with HER2-low ILC had **worse disease-free survival** compared to HER2-negative ILC
2. Patients with HER2-low ILC were more likely to undergo **mastectomy** than lumpectomy
3. Patients with HER2-low ILC more likely to have **PR positive tumors**


Takeaway

Further investigation of the potential benefit of HER2 targeted therapy in HER2-low early-stage breast cancer, and specifically lobular cancer, is warranted to ensure optimal outcomes in this distinct tumor subtype.

HER2-Low status in early-stage invasive lobular carcinoma of the breast

Harriet Rothschild¹, Elle Clelland¹, Anne Patterson², Julissa Molina-Vega², Mandeep Kaur¹, W Fraser Symmans³, Christopher J Schwartz⁴, A Jo Chien⁵, Rita A Mukhtar²

Methods





HER2 classification by IHC and FISH

- HER2-negative: IHC = 0
- HER2-low: IHC = 1+ or 2+ with negative FISH
- HER2-positive: IHC = 3+ or FISH ratio ≥ 2

Disease Free Survival			
	Hazard ratio	95% CI	P
HER2 status			
Negative (ref)			
Low	2.02	1.0-4.07	0.05*
Local Therapy			
Lumpectomy + radiation (ref)			
Lumpectomy	3.45	1.56-7.63	0.002*
Mastectomy	0.93	0.41-2.1	0.857
Mastectomy + radiation	1.01	0.39-2.62	0.982
Tumor size (per 1 cm)	1.13	1.04-1.24	0.005*
Number of positive lymph nodes (per 1 node)	1.09	1.05-1.14	<0.0001
ER status			
Negative (ref)			
Positive	0.49	0.17-1.4	0.193
PR status			
Negative (ref)			
Positive	0.41	0.21-0.79	0.008*

Multivariate Cox proportional hazards model for disease free survival in HER2-negative and HER2-low invasive lobular carcinoma (ILC) adjusting for local therapy, ER/PR status, tumor size, and number of positive nodes. Total $n = 427$.

Results



Acknowledgments: research supported by National Center for Advancing Translational Sciences, NIH, (UCSF-CTSI TL1)